COMPARATIVE ADHERENCE TRAJECTORIES OF ORAL FINGOLIMOD AND INJECTABLE DISEASE MODIFYING AGENTS IN MULTIPLE SCLEROSIS

被引：0
|
作者：
Earla, J. R. [1 ]
Hutton, G. J. [2 ]
Thornton, J. D. [1 ]
Chen, H. [1 ]
Johnson, M. L. [1 ]
Aparasu, R. [1 ]
机构：
[1] Univ Houston, Houston, TX USA
[2] Baylor Coll Med, Med Ctr, McNair Campus, Houston, TX 77030 USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND104
引用
收藏
页码：S279 / S279
页数：1
相关论文
共 50 条
  • [21] Adherence comparison in multiple sclerosis in a real-world setting: New oral versus classic injectable disease modifying treatments
    Alvarez-Payero, M.
    Gonzalez-Suarez, I.
    Alvarez-Rodriguez, E.
    Aguado-Valcarcel, M.
    Pineiro-Corrales, G.
    Munoz Garcia, D.
    Romero Lopez, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 310 - 310
  • [22] Adherence to oral versus injectable disease-modifying therapies for multiple sclerosis using French national health insurance databases
    Roux, J.
    Guilleux, A.
    Leray, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 899 - 900
  • [23] Does adherence to disease modifying agents influence quality of life in patients with multiple sclerosis?
    Cerghet, Mirela
    Elston-Lafata, Jennifer
    Schultz, Lonni
    Elias, Stanton
    Dobie, Elizabeth
    Tunceli, Kaan
    Reuther, Jackqueline
    NEUROLOGY, 2008, 70 (11) : A271 - A271
  • [24] An evaluation of adherence between patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug
    Phillips, A. L.
    Frean, M.
    Locklear, J. C.
    Menzin, J.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 603 - 603
  • [25] Disease-modifying agents in multiple sclerosis
    Coyle, P. K.
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2009, 12 (04) : 273 - 282
  • [26] Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
    Stefan Braune
    M. Lang
    A. Bergmann
    Journal of Neurology, 2016, 263 : 327 - 333
  • [27] Effect of Treatment Naivete on MRI Outcomes with Fingolimod or Injectable Disease-Modifying Therapies in Patients with Multiple Sclerosis: PREFERMS
    Hunter, Samuel F.
    Thomas, Florian P.
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 35 - 36
  • [28] Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis
    Eagle, Tessa
    Stuart, Fiona
    Chua, Alicia S.
    LaRussa, Allison
    Leclaire, Kaitlynne
    Cook, Sandra L.
    Chitnis, Tanuja
    Weiner, Howard L.
    Glanz, Bonnie I.
    Healy, Brian C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 196 - 201
  • [29] Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
    Braune, Stefan
    Lang, M.
    Bergmann, A.
    JOURNAL OF NEUROLOGY, 2016, 263 (02) : 327 - 333
  • [30] Effect of Treatment Naivete on MRI Outcomes with Fingolimod or Injectable Disease-Modifying Therapies in Patients with Multiple Sclerosis: PREFERMS
    Hunter, Samuel F.
    Thomas, Florian P.
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    Cree, Bruce A. C.
    NEUROLOGY, 2019, 92 (15)
12345